JP2023540240A - 放射性薬剤および方法 - Google Patents

放射性薬剤および方法 Download PDF

Info

Publication number
JP2023540240A
JP2023540240A JP2023513672A JP2023513672A JP2023540240A JP 2023540240 A JP2023540240 A JP 2023540240A JP 2023513672 A JP2023513672 A JP 2023513672A JP 2023513672 A JP2023513672 A JP 2023513672A JP 2023540240 A JP2023540240 A JP 2023540240A
Authority
JP
Japan
Prior art keywords
dotatate
amount
compounds
lutetium
octreotate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540240A5 (enExample
Inventor
ジョー マッカン
ユスティナ ケリー
ポール ビローネ
Original Assignee
センター フォー プローブ ディベロップメント アンド コマーシャリゼーション （シーピーディーシー）
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by センター フォー プローブ ディベロップメント アンド コマーシャリゼーション （シーピーディーシー） filed Critical センター フォー プローブ ディベロップメント アンド コマーシャリゼーション （シーピーディーシー）
Publication of JP2023540240A publication Critical patent/JP2023540240A/ja
Publication of JP2023540240A5 publication Critical patent/JP2023540240A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023513672A 2020-08-27 2021-08-27 放射性薬剤および方法 Pending JP2023540240A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063071138P 2020-08-27 2020-08-27
US63/071,138 2020-08-27
PCT/IB2021/000589 WO2022043754A2 (en) 2020-08-27 2021-08-27 Radiopharmaceutical and methods

Publications (2)

Publication Number Publication Date
JP2023540240A true JP2023540240A (ja) 2023-09-22
JP2023540240A5 JP2023540240A5 (enExample) 2024-09-04

Family

ID=80352743

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513672A Pending JP2023540240A (ja) 2020-08-27 2021-08-27 放射性薬剤および方法

Country Status (9)

Country Link
US (2) US11439714B2 (enExample)
EP (1) EP4204011A4 (enExample)
JP (1) JP2023540240A (enExample)
KR (1) KR20240121161A (enExample)
CN (1) CN116528904A (enExample)
AU (1) AU2021330382A1 (enExample)
CA (1) CA3190855A1 (enExample)
TW (1) TW202227143A (enExample)
WO (1) WO2022043754A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204872A2 (en) * 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Igf-1r monoclonal antibodies and uses thereof
JP2023539990A (ja) 2020-07-13 2023-09-21 ポイント バイオファーマ インコーポレイテッド 放射性薬剤および方法
WO2023164769A1 (en) * 2022-03-02 2023-09-07 Point Biopharma, Inc. Radiopharmaceutical and methods
CN115015441B (zh) * 2022-07-14 2023-08-18 原子高科股份有限公司 一种测定镥[177Lu]氧奥曲肽注射液中稳定剂含量的方法
WO2025171492A1 (en) 2024-02-14 2025-08-21 Alpha-9 Oncology Inc. Stable radiopharmaceutical compositions and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020064693A1 (en) * 2018-09-25 2020-04-02 Advanced Accelerator Applications (Italy) Srl Combination therapy
WO2020088767A1 (en) * 2018-10-31 2020-05-07 Advanced Accelerator Applications (Italy) Srl Methods for synthesis of radionuclide complex

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1096278A (en) 1913-08-25 1914-05-12 American Radiator Co Service-outlet fitting for pneumatic cleaning systems.
US6066309A (en) 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US6358245B1 (en) 1998-02-19 2002-03-19 Curon Medical, Inc. Graphical user interface for association with an electrode structure deployed in contact with a tissue region
EP1596705B1 (en) 2003-02-05 2018-09-12 Arthrocare Corporation Temperature indicating electrosurgical apparatus
CN100418585C (zh) 2003-07-24 2008-09-17 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
HK1254404A1 (zh) * 2015-06-25 2019-07-19 Advanced Accelerator Applications 治疗过度表达生长抑素受体的神经内分泌肿瘤的方法
CN115089242A (zh) 2016-05-23 2022-09-23 Ip2Ipo创新有限公司 末端执行器和持针器
US10537399B2 (en) 2016-08-16 2020-01-21 Ethicon Llc Surgical tool positioning based on sensed parameters
US10537394B2 (en) 2016-12-19 2020-01-21 Ethicon Llc Hot device indication of video display
US20200030466A1 (en) * 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) Srl Stable, concentrated radionuclide complex solutions
US10596276B2 (en) * 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020064693A1 (en) * 2018-09-25 2020-04-02 Advanced Accelerator Applications (Italy) Srl Combination therapy
WO2020088767A1 (en) * 2018-10-31 2020-05-07 Advanced Accelerator Applications (Italy) Srl Methods for synthesis of radionuclide complex

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANCER BIOTHER RADIOPHARM, vol. 26(3), JPN6025031323, 2011, pages 395 - 400, ISSN: 0005657234 *
J. LABEL COMPD. RADIOPHARM., vol. 58, JPN6025031322, 2015, pages 166 - 172, ISSN: 0005657233 *

Also Published As

Publication number Publication date
US20220387637A1 (en) 2022-12-08
WO2022043754A2 (en) 2022-03-03
US20220062447A1 (en) 2022-03-03
EP4204011A4 (en) 2025-06-18
TW202227143A (zh) 2022-07-16
WO2022043754A3 (en) 2022-04-07
CN116528904A (zh) 2023-08-01
CA3190855A1 (en) 2022-03-03
US11439714B2 (en) 2022-09-13
AU2021330382A9 (en) 2024-02-08
EP4204011A2 (en) 2023-07-05
AU2021330382A1 (en) 2023-05-04
KR20240121161A (ko) 2024-08-08

Similar Documents

Publication Publication Date Title
US12558440B2 (en) Radiopharmaceutical and methods
US11439714B2 (en) Radiopharmaceutical and methods
US11129912B1 (en) Radiopharmaceutical and methods
US20080267868A1 (en) Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex
KR100650506B1 (ko) 방사성 의약품용 레늄-트리카보닐 착물 및 그 전구체의제조방법
WO2023215333A1 (en) Radiopharmaceutical and methods
CN116547007A (zh) 放射性药物和方法
JP7804652B2 (ja) ６４Ｃｕ－ＤＯＴＡＴＡＴＥのスケールアップのための放射標識および製剤化
JPH07505621A (ja) 外科手術中における腫瘍組織の検出および探知法
HK40088578A (en) Radiopharmaceutical and methods
EP4486397A1 (en) Radiopharmaceutical and methods
CN118742332A (zh) 放射性药物和方法
Seifert et al. Preparation and biological characterization of isomeric 188Re (V) oxocomplexes with tetradentate S4 ligands derived from meso-dimercaptosuccinic acid for labeling of biomolecules
US11723992B2 (en) Method for extraction and purification of 68GA
WO2026020383A1 (zh) Ark组合物及其在肿瘤诊断中的应用
WO2026025213A1 (zh) 一种含rgd多肽的组合物及其应用
WO2021108474A1 (en) Method for extraction and purification of ai18f-labeled hbed conjugates

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230704

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240815

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240802

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240807

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260127